Media coverage about Perrigo (NYSE:PRGO) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Perrigo earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.6033438040492 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Podophyllin Market Top Manufacturers by 2023: Himpharm, Haoxuan, MP Biomedicals, Haoxiang and Perrigo (themobileherald.com)
- Watch-list Stock of Traders: Perrigo Company plc (PRGO) stock price is at $82.77 on volume of 637322 shares with … (nasdaqexpress.com)
- Is technical analysis on Perrigo Company plc (PRGO) is useful? (wallstreetmorning.com)
- Perrigo Company (NYSE:PRGO) – Important Factors to Analyse A Good Investment (nasdaqjournal.com)
- Locals still fighting against I-77 toll lane project (fox46charlotte.com)
NYSE:PRGO traded down $0.04 on Thursday, reaching $82.73. 819,328 shares of the stock traded hands, compared to its average volume of 1,014,821. The company has a market capitalization of $11,615.96, a PE ratio of 16.78, a P/E/G ratio of 2.05 and a beta of 0.76. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.96. Perrigo has a 1-year low of $63.68 and a 1-year high of $95.93.
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 20th. Shareholders of record on Friday, March 2nd were given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend was Thursday, March 1st. This is an increase from Perrigo’s previous quarterly dividend of $0.16. Perrigo’s dividend payout ratio is currently 15.42%.
Several research firms have recently issued reports on PRGO. Canaccord Genuity set a $105.00 price objective on Perrigo and gave the company a “buy” rating in a research note on Monday. Oppenheimer set a $98.00 price objective on Perrigo and gave the company a “buy” rating in a research note on Monday, March 5th. JPMorgan Chase reaffirmed a “neutral” rating and issued a $83.00 price objective (up previously from $82.00) on shares of Perrigo in a research note on Monday, March 5th. Finally, Cantor Fitzgerald set a $107.00 price objective on Perrigo and gave the company a “buy” rating in a research note on Thursday, March 1st. One research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $91.88.
In other news, CEO Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was acquired at an average price of $81.85 per share, with a total value of $613,875.00. Following the transaction, the chief executive officer now owns 4,900 shares of the company’s stock, valued at approximately $401,065. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 6.90% of the company’s stock.
WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://weekherald.com/2018/04/19/perrigo-prgo-earns-news-impact-score-of-0-09.html.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.